reports
1 director bought
A director at Biolase Inc bought 25,000 shares at 1.671USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...
BIOLASE Announces Expiration of Rights Offering
IRVINE, Calif.--(BUSINESS WIRE)-- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced today that the subscription period for its previously announced rights offering to holders of shares of its common stock expired at 5:00 p.m., Eastern Time, on November 29, 2017, and these rights are no longer exercisable. The Company received basic subscriptions and over-subscriptions for a total of 26,307,719 shares, exceeding the 26,302,703 shares offered in the rights offering. Available shares will be distributed...
BIOLASE to Conduct Demos of Portable Waterlase Expressâ„¢ All-Tissue L...
IRVINE, Calif.--(BUSINESS WIRE)-- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced today that it will be conducting demonstrations of its recently launched Waterlase Express all-tissue laser system at the Greater New York Dental Meeting next week at the Jacob K. Javits Convention Center. Dr. Samuel B. Low, the company’s chief dental officer, will also be presenting two continuing education workshops at the conference. The sessions will address how dentists can properly incorporate lasers into their practice ...
BIOLASE to Present at the Singular Research Best of the Uncovered 12th...
IRVINE, Calif.--(BUSINESS WIRE)-- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced that it is scheduled to present at the Singular Research Best of the Uncovered 12th Annual Conference 2017 on Monday, December 4, 2017, at 3:00 PM Pacific Time. BIOLASE President and Chief Executive Officer Harold C. Flynn, Jr. will be giving the presentation and meeting with investors. The conference is being held at the Hotel Angeleno, 170 North Church Lane, Los Angeles, CA 90049. A live webcast and 90-day rep...
BIOLASE Announces Commencement of Rights Offering
IRVINE, Calif.--(BUSINESS WIRE)-- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced that it has commenced its previously announced rights offering to holders of shares of its common stock. Under the terms of the rights offering, the Company distributed to its shareholders as of 5:00 p.m., Eastern Time, on November 8, 2017, the record date, 0.346 subscription rights exercisable for each share of the Company’s common stock owned. Each whole subscription right entitles the holder to purchase one s...
BIOLASE Announces Terms of Rights Offering
IRVINE, Calif.--(BUSINESS WIRE)-- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced the terms of its previously announced rights offering to holders of shares of its common stock. Upon commencement of the rights offering on November 8, 2017, the Company will distribute to its shareholders as of 5:00 p.m., Eastern Time, on November 8, 2017, the record date, subscription rights exercisable for each share of the Company’s common stock owned. Each whole subscription right will entitle the holder to...
BIOLASE Reports 2017 Third Quarter and Nine-Month Results
IRVINE, Calif.--(BUSINESS WIRE)-- BIOLASE, Inc. (NASDAQ:BIOL), the global leader in dental lasers, today reported its financial results for its third quarter and the nine months ended September 30, 2017. Waterlase Express™ placements in the U.S. during this year’s third quarter nearly doubled for the second consecutive quarter. The Company’s strategy of increasing its focus on new customers in the much larger “Early Majority” market segment resulted in new customers representing three-quarters of the all-tissue laser systems ...
BIOLASE Appoints Richard B. Lanman to Board of Directors
IRVINE, Calif.--(BUSINESS WIRE)-- BIOLASE, Inc. (NASDAQ:BIOL), the global leader in dental lasers, today announced that it has appointed Richard B. Lanman, M.D., a well-known biotechnology entrepreneur who specializes in accelerating the development and adoption of novel medical technologies, to its Board of Directors, effective November 1, 2017. The appointment of Dr. Lanman replaces outgoing director Fredrick H. Moll, M.D., who is resigning from the Board effective November 11, 2017, due to his commitments associated with his role a...
BIOLASE Announces Record Date for Previously Announced Proposed Rights...
IRVINE, Calif.--(BUSINESS WIRE)-- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced that its Board of Directors has set the record date of 5:00 p.m., Eastern Time on November 8, 2017, for its previously announced proposed rights offering to holders of shares of its common stock. The remaining terms of the rights offering, including the subscription price, will be set prior to November 8, 2017. A Registration Statement relating to these securities has been filed with the SEC but has not yet beco...
BIOLASE® to Host 2017 Third Quarter Financial Results Conference Call...
IRVINE, Calif.--(BUSINESS WIRE)-- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced today that the Company will host a conference call on Wednesday, November 1, 2017, at 4:30 p.m. Eastern Time to discuss its operating results for the third quarter and nine months ended September 30, 2017, and to answer questions. A press release disclosing the Company's financial results will be distributed at approximately 4:05 p.m. Eastern Time that same day. Phone ParticipationTo listen to the conference call live...
BIOLASE Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4...
IRVINE, Calif.--(BUSINESS WIRE)-- BIOLASE, Inc. (NASDAQ:BIOL), the global leader in dental lasers, today announced that on October 2, 2017, John R. Beaver, the Company’s Senior Vice President and Chief Financial Officer, received a stock option to purchase 600,000 shares of the Company’s common stock with an exercise price of $0.59 per share, the closing price per share on October 2, 2017. Of the total 600,000 shares covered by the options, 100,000 shares vest on the one-year anniversary of grant, 300,000 shares vest ratably on a mont...
BIOLASE Names John Beaver Senior Vice President, Chief Financial Offic...
IRVINE, Calif.--(BUSINESS WIRE)-- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced today that veteran financial executive John R. Beaver has been named Senior Vice President and Chief Financial Officer, effective October 1, 2017. He reports directly to President and CEO Harold C. Flynn, Jr. Mr. Beaver, 56, brings proven leadership and technical experience in finance and business management in both public and private companies. “John’s business expertise, particularly in terms of building, ...
BIOLASE Announces Plans for Rights Offering to Stockholders
IRVINE, Calif.--(BUSINESS WIRE)-- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced that it has filed a Registration Statement on Form S-1 with the Securities and Exchange Commission (the “SEC”) for a rights offering to existing holders of its common stock. If the rights offering is successful, the Company expects to receive gross proceeds of approximately $8,000,000 to $12,000,000 before expenses. Certain affiliates of Larry Feinberg and certain affiliates of Jack Schuler have each agreed with the Comp...
BIOLASE Names Jonathan T. Lord Chairman of the Board
IRVINE, Calif.--(BUSINESS WIRE)-- BIOLASE, Inc. (NASDAQ:BIOL), the global leader in dental lasers, today announced that on September 1, 2017 it named Jonathan “Jack” T. Lord, M.D., a nationally recognized leader in healthcare innovation, as its new Chairman of the Board. Dr. Lord replaces outgoing Chairman Paul N. Clark, who resigned from the Board of Directors effective September 11, 2017, due to other time commitments. Dr. Lord, 62, was appointed to the BIOLASE Board in August 2014 and serves as Chairman of the Company’s Co...
BIOLASE Reports 2017 Second Quarter and Six-Month Results
IRVINE, Calif.--(BUSINESS WIRE)-- BIOLASE, Inc. (NASDAQ:BIOL), the global leader in dental lasers, today reported its financial results for its second quarter and six months ended June 30, 2017. Waterlase Express™ placements continued to ramp up following its February launch; however, overall revenue fell short of internal expectations and declined when compared to the 2016 second quarter. This was due in part to nearly $400,000 of OEM imaging backorders at quarter’s end, a year-over-year decline in current customer upgrade ...
BIOLASE® to Host 2017 Second Quarter Financial Results Conference Cal...
IRVINE, Calif.--(BUSINESS WIRE)-- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced today that the Company will host a conference call on Monday, August 7, 2017, at 4:30 p.m. Eastern Time to discuss its operating results for the second quarter and six months ended June 30, 2017, and to answer questions. A press release disclosing the Company's financial results will be distributed at approximately 4:05 p.m. Eastern Time that same day. Phone Participation To listen to the conference ca...
BIOLASE Announces Management Change
IRVINE, Calif.--(BUSINESS WIRE)-- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced today that it has accepted the resignation of recently named Chief Financial Officer Mark J. Nelson, who resigned to pursue an unsolicited and lucrative business opportunity with a former employer. The Company will be initiating a search for a Chief Financial Officer. “We were very disappointed that Mark was faced with the difficult decision to leave BIOLASE after recently starting as CFO,” said President and CEO Haro...
BIOLASE Reports 2017 First Quarter Results
IRVINE, Calif.--(BUSINESS WIRE)-- BIOLASE, Inc. (NASDAQ:BIOL), the global leader in dental lasers, today reported its financial results for its first quarter ended March 31, 2017. 2017 First Quarter highlights with comparisons to 2016 First Quarter include: Worldwide revenue of $10.9 million, a decline of 1%, driven by a 13% decline in international sales, substantially offset by a 7% increase in U.S. revenue 25% increase in U.S. Waterlase revenue and a 43% increase in ...
BIOLASE® to Host 2017 First Quarter Financial Results Conference Call...
IRVINE, Calif.--(BUSINESS WIRE)-- BIOLASE, Inc. (NASDAQ:BIOL), the global leader in dental lasers, announced today that the Company will host a conference call on Wednesday, May 3, 2017, at 4:30 p.m. Eastern Time to discuss its operating results for its first quarter ended March 31, 2017, and to answer questions. A press release disclosing the Company's financial results will be distributed at approximately 4:05 p.m. Eastern Time that same day. Phone ParticipationTo listen to the conference call live via telephone, dia...
BIOLASE to Raise $10.5 Million from Institutional and Individual Inves...
IRVINE, Calif.--(BUSINESS WIRE)-- BIOLASE, Inc. (NASDAQ:BIOL), the global leader in dental lasers, announced today that investors including Oracle Partners, L.P., Oracle Ten Fund Master, L.P. and Oracle Institutional Partners L.P., the Schuler Family Foundation, and certain BIOLASE directors and officers, have agreed to purchase $10.0 million of unregistered shares of the Company’s convertible preferred stock and $0.5 million of warrants to purchase unregistered shares of the Company’s common stock, in a private placement transaction....
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.